November 2, 2012. Members of the Patient, Consumer, and Public Health Coalition welcome the opportunity to provide our views regarding pharmacy compounding. Stronger regulations are clearly needed to prevent tragedies such as the contaminated steroid injections that have already resulted in 356 cases of fungal meningitis and 28 deaths. Current laws and regulations regarding compounding pharmacies have resulted in giant loopholes that allow medical products that are neither safe nor effective to be sold throughout the country, putting patients’ lives at risk.
Read More »On Health Policy
Coalition Letter Regarding FDA’s Recent HELP Committee Testimony on Pharmacy Compounding
November 30, 2012. As members of the Patient, Consumer, and Public Health Coalition, we welcome the opportunity to provide our views regarding FDA Commissioner Margaret Hamburg’s November 15, 2012 testimony at the HELP Committee hearing, “Pharmacy Compounding: Implications of 2012 Meningitis Outbreak.”
Read More »Coalition Letter to Congressman Edward J. Markey Regarding the VALID Compounding Act of 2012
October 31, 2012. As members of the Patient, Consumer, and Public Health Coalition, we thank you for your commitment to the health of patients and consumers by introducing the Verifying Authority and Legality in Drug (VALID) Compounding Act of 2012. This bill would strengthen FDA oversight of compounding pharmacies in several essential ways, and is clearly needed to prevent tragedies such as the contaminated steroid injections that have already resulted in 356 cases of fungal meningitis and 28 deaths.
Read More »Coalition Letter to CMS Urging the Release of the Sunshine Act Final Regulations
November 15, 2012. As members of the Patient, Consumer, and Public Health Coalition, we strongly urge CMS to release the Sunshine Act final regulations as quickly as possible.
Read More »Coalition Letter to HELP Committee Regarding Track and Trace Legislation
November 7, 2012. We are deeply concerned about the current and growing risk to the U.S. pharmaceutical supply, a threat that can best be addressed through a meaningful national system to track and authenticate pharmaceutical products as they move from manufacturer to wholesaler to pharmacy to patient.
Read More »